Darolutamide
💊 Brand Formulations & Prices
2 brands sorted by unit price📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesDamid is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer.
The recommended dose of Darolutamide is 600 mg (two 300 mg tablets) administered orally twice daily, equivalent to a total dose of 1200 mg. Swallow tablets whole with food. Advice patients to take any missed dose as soon as they remember prior to the next scheduled dose, and not to take two doses together to make up for a missed dose. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
Fatigue
Pain in extremity
Rash
Damid can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception.
Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, keto-darolutamide, exhibited similar in vitro activity to Darolutamide. In addition, Darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer.